Antibody or ligand-mediated targeting of liposomal anticancer drugs to antigens expressed selectively or over-expressed on tumor cells is increasingly being recognized as an effective strategy for increasing the therapeutic indices of anticancer drugs. This review summarizes some recent advances in the field of ligand-targeted liposomes (LTLs) for the delivery of anticancer drugs. New approaches used in the design and optimization of LTLs is discussed and the advantages and potential problems associated with their therapeutic applications are described. New technologies are widening the spectrum of ligands available for targeting and are allowing choices to be made regarding affinity, internalization and size. The time is rapidly approaching where we will see translation of anticancer drugs entrapped in LTLs to the clinic.

中文翻译：

---

靶向配体的脂质体抗癌药。

抗体或配体介导的脂质体抗癌药靶向在肿瘤细胞上选择性表达或过度表达的抗原的作用日益被认为是提高抗癌药治疗指数的有效策略。这篇综述总结了在抗癌药物的配体靶向脂质体（LTL）领域中的一些最新进展。讨论了用于LTL设计和优化的新方法，并描述了与LTL治疗应用相关的优点和潜在问题。新技术拓宽了可用于靶向的配体范围，并允许在亲和力，内在化和大小方面做出选择。时间很快就要到了，我们将看到残留在LTL中的抗癌药物向临床翻译。